Mario Contreraz named administrator of IU cancer center clinical trials office

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mario Contreraz was named administrator of the Indiana University Melvin and Bren Simon Cancer Center’s Clinical Trials Office.

As administrator, Contreraz will provide overall direction for the strategy and vision for the Clinical Trials Office to ensure all NCI criteria and guidelines are met. He will also serve as a liaison between the administrative staff and the sponsors, collaborators, and regulatory agencies.

Contreraz had served as interim administrator for the Clinical Trials Office during the recruitment process. He initially joined the Clinical Trials Office in May 2016 as the research nurse administrator.

Prior to joining the CTO, Contreraz was a clinical research manager at the IU School of Medicine’s clinical research center, a clinical research nurse at the Krannert Institute of Cardiology, a nursing associate at Eli Lilly and Company, and an ER nurse at Eskenazi Health. He holds both a master’s of nurse administration, a master’s of business administration from Anderson University, and a bachelor’s degree in nursing from Ball State University.

Table of Contents

YOU MAY BE INTERESTED IN

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login